Group 1 - U.S. stock futures are higher, with Nasdaq futures gaining approximately 1.5% [1] - Monday.Com Ltd is expected to report quarterly earnings of 88 cents per share, an increase from 85 cents per share year-over-year [2] - The consensus estimate for monday.com's quarterly revenue is $312.26 million, up from $251 million a year earlier [2] Group 2 - Monday.Com shares fell 2.6% to $184.70 in pre-market trading [2] - Metsera Inc shares dipped 15% to $70.68 in pre-market trading following Pfizer's $10 billion acquisition deal [4] - Ionis Pharmaceuticals Inc declined 11.5% to $65.00 after disclosing results from pivotal Phase 3 studies [4] - Other companies such as UniQure NV, Oscar Health Inc, Centene Corp, and Immunovant Inc also experienced declines in pre-market trading [4]

Pfizer has submitted a sweetened bid for obesity drug startup Metsera Inc. as its fight against rival Novo continues to escalate, according to sources https://t.co/QqYU5Umf8d ...

The takeover saga for obesity drugmaker Metsera isn’t over yet: Here's your Evening Briefing https://t.co/4p6saZ0FsH ...

Four days. That's all Pfizer has to make its move in the ongoing saga to buy obesity drugmaker Metsera now that Novo has shown up with a surprise counterbid https://t.co/AfXznSvvbr ...

Corporate Leadership - Novo Nordisk's former CEO returns as chairman to aid in the company's revival effort [1] Industry Focus - The company focuses on obesity drug development [1]

Core Viewpoint - Metsera's experimental obesity drug demonstrated significant weight loss and favorable tolerability in mid-stage studies [1] Group 1 - The drug showed promising results in terms of weight loss during the mid-stage trials [1] - Tolerability of the drug was reported to be favorable, indicating a potentially positive safety profile [1]

Hengrui and its US partner said their obesity drug candidate succeeded in a late-stage China study https://t.co/VDCShdXlw3 ...